Mindfulness Meditation in Hemodialysis Patients
MIND-HD
The Effect of Mindfulness Meditation on Sleep, Stress, and Symptoms in Hemodialysis Patients: A Randomized Controlled Trial
1 other identifier
interventional
50
1 country
4
Brief Summary
This randomised controlled study aims to evaluate the effects of mindfulness meditation on sleep quality, perceived stress and symptoms levels ion hemodialysis patients. Participants in the intervention group will receive a 4 week mindfulness meditation program in addition to routine care. Outcomes will be assessed before and after the intervention using validated measurement tools.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Apr 2026
Shorter than P25 for not_applicable
4 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 15, 2026
CompletedFirst Submitted
Initial submission to the registry
May 26, 2026
CompletedFirst Posted
Study publicly available on registry
June 2, 2026
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
August 1, 2026
June 2, 2026
June 1, 2026
3 months
May 26, 2026
June 1, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Pittsburgh Sleep Quality İndex (PSQİ) Score
Pittsburgh Sleep Quality İndex (PSQİ) will be used to assess sleep quality in hemodialysis patients receiving mindfulness meditation intervention. The total PSQİ score ranges from 0 to 21, with higher scores indicating poorer sleep quality.
Baseline and 4 weeks after intervention
Perceived Stress Scale (PSS) Score
The Perceived Stress Scale (PSS) will be used to assess stress levels in hemodialysis patients receiving mindfulness meditation intervention. Scores range from 0 to 40, with higher scores indicating higher perceived stress.
Baseline and 4 week after intervention.
Dialysis Symptom İndex (DSİ)
TheDialysis Symptom İndex (DSİ) will be used to assess symptom burden in hemodialysis patients receiving mindfulness meditation intervention. The total score ranges from 0 to 150, with higher scores indicating greater symptom burden.
Baseline and 4 weeks after intervention.
Study Arms (2)
Mindfulness Meditation Group
EXPERIMENTALParticipants in this group will receive a 4 week meditation program in addition to routine hemodialysis care.
Control Group
OTHERParticipants in this group will receive rouyine hemodialysis care without mindfulness meditation intervention.
Interventions
Participants in the intervention group will receive a 4 week mindfulness meditation program consisting of weekly guided mindfulness sessions and home practices. The program is designed to improve sleep quality, reduce stress levels, and manage symptoms in hemodialysis patients.
Participants in the control group will receive routine care provided in the hemodialysis unit without mindfulness meditation intervention.
Eligibility Criteria
You may qualify if:
- Patients aged between 18 and 75 years
- Patients receiving hemodialysis treatment for at least 3 months
- Patients with cognitive functions suitable for the intervention (dementia score ≥21)
- Patient without hearing, vision or communication problems
- Patients without a psychiatric diagnosis
- Patients able to use a smartphone or tablet
- Patients not participating in another study
- Patients not using sleep medication or antipsychotic drugs
You may not qualify if:
- Patients younger than 18 years or older than 75 years
- Patients receiving hemodialysis treatment for less than 3 months
- Patients with cognitive impairment unsuitable for the intervention (dementia score ≤21)
- Patient with hearing, vision or communication disabilities
- Patients diagnosed with psychiatric disorders
- Patients unable to use a smartphone or tablet
- Patients participating in another study
- Patients using sleep medication or antipsychotic drugs
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (4)
Famagusta State Hospital
Famagusta, Cyprus
Dr. Akçiçek State Hospital
Kyrenia, Cyprus
Cengiz Topel State Hospital
Lefka, Cyprus
Dr. Burhan Nalbantoğlu State Hospital
Nicosia, Cyprus
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Sevda Sahin, RN, PhD Candidate
Cyprus Aydin University
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- RN, PhD Candidate
Study Record Dates
First Submitted
May 26, 2026
First Posted
June 2, 2026
Study Start
April 15, 2026
Primary Completion (Estimated)
July 1, 2026
Study Completion (Estimated)
August 1, 2026
Last Updated
June 2, 2026
Record last verified: 2026-06